Squarepoint
IMMX icon

Squarepoint’s Immix Biopharma IMMX Stock Holding History

Squarepoint’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$405K Buy
44,490
+22,990
+107% +$169K ﹤0.01% 3473
2025
Q4 		$112K Buy
+21,500
New +$88.5K ﹤0.01% 4017
2024
Q3 		– Sell
-23,010
Closed -$45.6K – 4369
2024
Q2 		$45.6K Buy
+23,010
New +$52.9K ﹤0.01% 3912

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Squarepoint's IMMX Position: Q1 2026 in Review

Squarepoint increased its Immix Biopharma (IMMX) stake by 107% in Q1 2026, buying an estimated $169K and bringing the position to 44,490 shares worth $405K. The position accounts for ﹤0.01% of the portfolio, ranked #3473.

Squarepoint first reported a position in IMMX in Q2 2024 and has held it in 3 quarters since. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • Squarepoint held 44,490 shares of Immix Biopharma worth $405K as of Q1 2026.
  • Squarepoint bought 22,990 Immix Biopharma shares in Q1 2026, an estimated $169K.
  • Immix Biopharma made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3473 holding.
  • Squarepoint first reported a position in Immix Biopharma in Q2 2024 and has held it in 3 quarters since.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.